Alliance Pharmaceuticals Limited, a wholly owned subsidiary of Alliance Pharma, is paying an initial GBP4.2m to purchase the brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. These products are sold mainly in the UK and France.
In a statement, Alliance said that it expects the acquired products to generate incremental contribution before financing costs of approximately GBP1.1m per annum.
On top of the initial cash consideration of GBP4.2m, a further sum of up to GBP1.0m may become payable over the next three years, dependent on sales of the brands.
Alliance also announced that it has recently appointed a country manager for France, Dr Philippe Pasdelou, who will manage the sales of the anti-malarial brands in France. The company has also appointed Lars Borger as country manager for Germany, Switzerland and Austria.
(USD1=GBP0.64)
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia